Doxorubicin-based adjuvant chemotherapy in elderly breast cancer patients: The M.D. Anderson experience, with long-term follow-up

Annals of Oncology

Volumn 11, Issue 12, 2000, Pages 1597-1601

  Ibrahim, N K ^a   Buzdar, A U ^a   Asmar, L ^a   Theriault, R L ^a   Hortobagyi, G N ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Adjuvant chemotherapy; Breast cancer; Doxorubicin; Elderly patients

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; METHOTREXATE; PREDNISONE; VINBLASTINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADULT; AGED; AGING; ARTICLE; BLOOD TOXICITY; BREAST CANCER; CANCER PATIENT; CANCER SURVIVAL; CARDIOMYOPATHY; EXPERIENCE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HUMAN; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; SURVIVAL RATE; VOMITING;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS; DISEASE-FREE SURVIVAL; DOXORUBICIN; FEMALE; HEALTH STATUS; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; STROKE VOLUME;

EID: 0034488070     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008315312795     Document Type: Article

References (20)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials
2. Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer
3. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: Results from the National Surgical Adjuvant Breast and Bowel Project B-16
4. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer
5. Adjuvant treatment of node-positive breast cancer with cyclophosphamide, doxorubicin, fluorouracil, and vincristine versus cyclophosphamide, methotrexate, and fluorouracil: Final report after a 16-year median follow-up duration
6. Adjuvant cyclophosphamide, methotrexate, and fluorouracil versus fluorouracil, epirubicin, and cyclophosphamide chemotherapy in premenopausal women with axillary node-positive operable breast cancer: Results of a randomized trial
7. Adjuvant therapy with a doxorubicin regimen and long-term tamoxifen in premenopausal breast cancer patients: An Eastern Cooperative Oncology Group trial
8. Doxorubicincontaining regimens for the treatment of stage II breast cancer: The National Surgical Adjuvant Breast and Bowel Project experience
9. Age-related patterns of care: Evidence against ageism in the treatment of early-stage breast cancer
10. The effect of aging on the utilization of chemotherapy for metastatic breast cancer A population-based study
11. The effect of comorbidity on three-year survival of women with primary breast cancer
12. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer: Tolerance and outcome
13. Chemotherapy of metastatic breast cancer in the elderly: The Piedmont Oncology Association experience
14. Clinical trials and drug toxicity in the elderly: The experience of the Eastern Cooperative Oncology Group
15. Psychosocial consequences of cancer chemotherapy for elderly patients
16. Doxurubicin-induced congestive heart failure in elderly patients with metastatic breast cancer, with long-term follow-up: The M.D. Anderson experience
17. Representation of older patients in cancer treatment trials
18. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: The elimination of age trends in toxicity by using doses based on creatinine clearance
19. Information needs and decisional preferences in women with breast cancer
20. The treatment decision-making process: Age differences in a sample of women recently diagnosed with nonrecurrent, early-stage breast cancer